Anti-infectives: Targeting SARS
Transcript of Anti-infectives: Targeting SARS
686 | SEPTEMBER 2004 | VOLUME 2 www.nature.com/reviews/micro
So far, many different classes of antimicrobialpeptides have been identified in mammals,including α-, β- and θ-defensins and catheli-cidins. For more information on defensins inprimates, see the review by Robert Lehrer onpage 727 of this issue.
Hornef et al. were interested in a family ofmouse-intestine-specific CRS (cryptdin-relatedsequence) peptides. CRS mRNAs have beencharacterized previously but the peptideproducts have never been characterized before.Using mRNA from intestinal tissue of healthymice, Hornef et al. identified 15 new cDNAsencoding CRS peptides, bringing the totalnumber of CRS peptide coding sequences to23, comparable to the number of mouse α-defensin genes. Each CRS gene encodes apeptide containing a pro-region that is cleavedoff during processing, leaving a mature cationicpeptide containing nine conserved cysteines.Of the 15 new sequences identified, most ofthe sequence variation observed was in thepro-region, and so a total of 7 mature peptideswere predicted by the coding sequences.
To screen for mature CRS peptides in vivo,whole mouse intestinal tissue was fractionatedby reverse-phase HPLC. Analysis of the massof fractions in the presence and absence of areducing agent indicated the presence of
dimers. To exclude the possibility that dimerformation was an experimental artefact, theextraction process was repeated in the pres-ence of an alkylating agent that inhibits theformation of disulphide bonds. This con-firmed that CRS peptides form covalentdimers in vivo. Six mature peptides were iden-tified in a variety of homo- and heterodimersand, additionally, four peptides were alsofound in truncated form. Examination of theantibacterial activity of synthetic CRS dimersshowed these agents had potent activity againstbacterial species including Salmonella entericaserovar Typhimurium and Streptococcus pyogenes,with no cytotoxicity.
The complement of antimicrobial peptidesvaries from species to species. This study hasrevealed that in mice, the complement of CRSpeptides matches that of the α-defensins innumber, and perhaps also in potency. The abil-ity to form hetero- and homodimers is a neattrick to expand the repertoire of intestinal pep-tide diversity and strengthen antimicrobialdefence.
Sheilagh Clarkson
References and linksORIGINAL RESEARCH PAPER Hornef, M. W. et al. Increaseddiversity of intestinal antimicrobial peptides by covalent dimerformation. Nature Immunol. 5, 836–843 (2004)
A new study published in the Proceedingsof the National Academy of Sciences (USA)has identified 15 compounds that arepotent against the severe acute respiratorysyndrome virus (SARS-CoV) in cell-basedassays, including two drugs that arecurrently in use and several that arealready in the clinical developmentpipeline.
The only available therapy for SARS-CoVis a combination of ribavirin andcorticosteroids, which is effective — butonly at concentrations that produce severeside effects. Since SARS was first isolated in2002, it has caused more than 700 deathsworldwide, so finding effective antivirals forSARS is a priority.
High-throughput screening requires asimple and reliable assay system. Wu et al.used a cell-based assay to screen more than10,000 compounds, all administered at 10µM, for inhibition of virus cytopathiceffects. From this primary screen, 50compounds were selected for furtheranalysis, first to determine if the compoundswere cytotoxic and second to measure the
concentration of the compound required toinhibit virus replication by 50% (EC
50).
The most potent inhibitor wasvalinomycin, a peptide insecticide with anEC
50of 0.85 µM. Aescin and reserpine,
already in use in Europe and the UnitedStates, respectively, were also active againstSARS-CoV, but neither drug is currentlyprescribed as an antiviral. Compounds thatare structurally similar to reserpine andaescin were also screened, resulting in 10new anti-SARS active compounds. Finally, apotent inhibitor of the HIV protease, TL-3,which is being developed as a treatment forAIDS in cats, was also effective against theSARS protease. These studies offer new hopefor rapidly available SARS therapeutics.
Susan Jones
References and linksORIGINAL RESEARCH PAPER Wu, C.-Y. et al. Smallmolecules targeting severe acute respiratory syndromehuman coronavirus. Proc. Natl Acad. Sci. USA 101,10012–10017 (2004) FURTHER READING Stadler, K. et al. SARS — beginningto understand a new virus. Nature Rev. Microbiol. 1, 209–218(2003)WEB SITEWong laboratory: http://wong.scripps.edu/
Targeting SARS
A N T I - I N F E C T I V E S
Diverse defence
I N N AT E I M M U N I T Y
R E S E A R C H H I G H L I G H T S
A report published in Nature Immunologypresents the first detailed characterization of anew family of antimicrobial peptides in themouse intestine.
Antimicrobial peptides are small, endoge-nous peptides containing <100 residues and arean important component of innate immunity.